Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g.,…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta…
May 2019 Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…
Heart failure with preserved ejection fraction (HFpEF) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that HFpEF accounts for nearly half of all CHF cases,…
A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic…
Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…
Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…
Market Outlook Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
For the estimated 5 million people in the United States with atrial fibrillation (AF), several treatment approaches can be used, each of which has a wide range of pharmacological options…